Transformation and Metastasis
CLINICAL RESEARCHERS
- Maria Teresa Soler Monsó
- Andrea Carolina Vethencourt Casado
POSTDOCTORAL RESEARCHERS (R2)
- Eva Maria Trinidad Alvarez
- Ana Sofia Semiao Da Rocha
CANCER
ONCOBELL
Scientific production
9
PAPERS
Impact factor: 120,427
4 PUBLICATIONS IN FIRST DECILE
6 PUBLICATIONS IN FIRST QUARTILE
8 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Benitez S, Cordero A, Santamaria PG, Redondo Pedraza J, Rocha AS, Collado Sole A, Jimenez M, Sanz Moreno A, Yoldi G, Santos JC, De Benedictis I, Gomez Aleza C, Da Silva Alvarez S, Troule K, Gomez Lopez G, Alcazar N, Palmero I, Collado M, Serrano M, Gonzalez Suarez E. RANK links senescence to stemness in the mammary epithelia, delaying tumor onset but increasing tumor aggressiveness. Dev Cell. 2021;56(12):1727-doi:10.1016/j.devcel.2021.04.022. IF:12,27.
- Ciscar M*, Trinidad EM*, Perez-Montoyo, H, Alsaleem M, Jimenez-Santos MJ, Toss M, Sanz-Moreno A, Vethencourt A, Perez-Chacon G, Petit A, Soler-Monsó MT Gomez-Miragaya J, Gomez-Aleza C, Jimenez M, Dobrolecki, LE, Lewis MT, A Bruna, S Mouron, M Quintela Fandino, F Al-Shahrour, A Martinez Aranda, Sierra A, Green AR, Rakha E and González-Suarez E. RANK expression is an independent factor of poor prognosis in estrogen receptor negative breast cancer and a therapeutic target in patients derived orthoxenografts. Biorxiv 2021. doi: 10.1101/2021.12.13.470911
- XY Woo, (60 authors), Enzo Medico*, Jeffrey H. Chuang*, PDXNET consortium & EurOPDX consortium. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat Genet 53, 86–99 (2021). https://doi.org/10.1038/s41588-020-00750-6
- Sanz Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galvan P, Benitez S, Gomez Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler Monso MT, Vinas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez Suarez E. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. BREAST CANCER RES. 2021;23(1):42-42. doi:10.1186/s13058-021-01390-2. IF:6,47.
- Vethencourt,AC,Trinidad,EM,Aleza,CG,Simon,SP,Petit,A,Soler,T,Urruticoechea,A,Martinez,AG,Garcia Tejedor,A,Pla,MJ,Capo,C,Gil,MG,Stradella,A,Fernadez,A,Penabad,SR,Cejuela,M,Vazquez,S,Iserte,A,Falo,C,Gonzalez Suarez,E. Immunomodulatory effect of denosumab in early breast cancer: Preliminary results of a randomized window-opportunity clinical trial D-Biomark. Ann. Oncol.2021.3226-26.doi:10.1016/j.annonc.2021.03.028.
Research highlights
PROJECTS
12 Competitive projects
2 Non-competitive projects
1 Clinical trial
PUBLISHED WORKS
1 thesis
NETWORKS
ENBDC
IABCR
EurOPDX
Selected projectes
- 21PSJ002. Estudio de biomarcadores de la actividad antitumoral del denosumab y su papel como modulador de la respuesta inmune en el cáncer de mama precoz: IO-D-BIOMARK. FUND. GRUPO ESP. INVEST. CÁNCER DE MAMA. 2021-2023. IP:VETHENCOURT CASADO,ANDREA CAROLINA.
- 20FIS036. CONTRATOS RIO HORTEGA. (CM19/00148). ISCIII. 2020-2022. IP:GONZALEZ SUAREZ,EVA.
- 16CEE012. PLEIO-RANK:Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity. (682935). COMISSIÓ EUROPEA. 2016-2023. IP:GONZALEZ SUAREZ,EVA.
- 18MEC027. AYUDAS JUAN DE LA CIERVA – INCORPORACION 2017. 2018-2021. IP:GONZALEZ SUAREZ,EVA.
- 18FIS036. CONTRATOS SARA BORRELL. ISCIII. 2018-2021. IP:GONZALEZ SUAREZ,EVA .